Post-translational modifications by the small ubiquitin-like modifier (SUMO) family are important in oncogenesis and cellular response to DNA damage. Recent findings indicate that the key oncogenic pathways driven by Myc and KRas are dependent on, or addicted to, SUMOylation. In one study, genome-wide siRNA knockdown identified the gene encoding the catalytic subunit of the SUMO activating enzyme (SAE), SAE2, as having the strongest synthetic lethal interaction with Myc hyperactivation. Similarly, genes encoding the SUMOylation enzymes were found to be critical for KRas-dependent tumorigenesis. Based on these findings, we hypothesize that the SAE is a novel target for developing anti-cancer therapeutics for cancers that are Myc-and KRas-dependent. The over-arching goal of this proposal is to test this hypothesis, and the proposed studies are enabled by our discovery of potent and specific SAE inhibitors that have selective toxicity to cancer cell lines that have high Myc-expression levels and/or KRas mutation. We propose to investigate the molecular mechanisms underlying the synthetic lethality of SUMOylation with Myc hyperactivation and KRas mutations in order to further validate the SAE as a potential cancer therapeutic target. In addition, we will investigate the structure-activity relationship of how the inhibitors interact with the SAE and inhibit its enzymatic activity, and use this information to guide further improvement of the inhibitors. These studies could potentially improve treatment of many cancers, as overexpression of Myc is estimated to contribute to 70% of all human cancers, and KRas is also frequently mutated in human cancers. However, both Myc and KRas have proven difficult to inhibit pharmacologically. Thus, the proposed studies will likely establis a new paradigm to target the SAE for the development of novel cancer therapies.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1 (09))
Program Officer
Janes, Daniel E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Wang, Jiin-Tarng; Xu, Xiaohua; Alontaga, Aileen Y et al. (2014) Impaired p32 regulation caused by the lymphoma-prone RECQ4 mutation drives mitochondrial dysfunction. Cell Rep 7:848-58
Chen, Chih-Hong; Namanja, Andrew T; Chen, Yuan (2014) Conformational flexibility and changes underlying activation of the SUMO-specific protease SENP1 by remote substrate binding. Nat Commun 5:4968
Madu, Ikenna G; Namanja, Andrew T; Su, Yang et al. (2013) Identification and characterization of a new chemotype of noncovalent SENP inhibitors. ACS Chem Biol 8:1435-41
Hu, Weidong; Namanja, Andrew T; Wong, Steven et al. (2012) Selective editing of Val and Leu methyl groups in high molecular weight protein NMR. J Biomol NMR 53:113-24
Li, Yi-Jia; Perkins, Angela L; Su, Yang et al. (2012) Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation. Proc Natl Acad Sci U S A 109:4092-7
Truong, Khue; Lee, Terry D; Chen, Yuan (2012) Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain inhibits E1 Cys domain enzymatic activity. J Biol Chem 287:15154-63
Namanja, Andrew T; Li, Yi-Jia; Su, Yang et al. (2012) Insights into high affinity small ubiquitin-like modifier (SUMO) recognition by SUMO-interacting motifs (SIMs) revealed by a combination of NMR and peptide array analysis. J Biol Chem 287:3231-40
Truong, Khue; Su, Yang; Song, Jing et al. (2011) Entropy-driven mechanism of an E3 ligase. Biochemistry 50:5757-66
Li, Y-J; Stark, J M; Chen, D J et al. (2010) Role of SUMO:SIM-mediated protein-protein interaction in non-homologous end joining. Oncogene 29:3509-18
Cano, Kristin E; Li, Yi-Jia; Chen, Yuan (2010) NMR metabolomic profiling reveals new roles of SUMOylation in DNA damage response. J Proteome Res 9:5382-8

Showing the most recent 10 out of 19 publications